Yang Yuan

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR-Positive, HER2-Negative Breast Cancer: A Retrospective Single-Centre Cohort Analysis.

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR-Positive, HER2-Negative Breast Cancer: A Retrospective Single-Centre Cohort Analysis.

Journal: Cancer medicine

Published: June 06, 2026

Chinese expert consensus on endocrine therapy for breast cancer (2026 edition).

Chinese expert consensus on endocrine therapy for breast cancer (2026 edition).

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: November 19, 2025

Real-World Treatment Patterns and Survival Outcomes in Metastatic Triple Negative Breast Cancer: Immunotherapy- Versus Anti-Angiogenic Therapy-Combined-With-Chemotherapy.

Real-World Treatment Patterns and Survival Outcomes in Metastatic Triple Negative Breast Cancer: Immunotherapy- Versus Anti-Angiogenic Therapy-Combined-With-Chemotherapy.

Journal: Cancer medicine

Published: June 02, 2025

Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging.

Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging.

Journal: Nature aging

Published: May 26, 2025

Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study.

Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study.

Journal: International journal of clinical oncology

Published: May 05, 2025

A real-world comparison of circulating tumor cells in breast cancer from China: Novel device, CTC counts and its overall survival.

A real-world comparison of circulating tumor cells in breast cancer from China: Novel device, CTC counts and its overall survival.

Journal: Heliyon

Published: October 23, 2023

A comparison between clinical decision support system and clinicians in breast cancer.

A comparison between clinical decision support system and clinicians in breast cancer.

Journal: Heliyon

Published: March 30, 2023

Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2- metastatic breast cancer.

Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2- metastatic breast cancer.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: February 06, 2023

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.

Journal: The oncologist

Published: December 22, 2022

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer.

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer.

Journal: Chinese medical journal

Published: October 16, 2022

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: September 13, 2022

Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study.

Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study.

Journal: Annals of translational medicine

Published: June 24, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026